Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
33 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-53 |
Cash Flow (TTM) (Millions $) |
-119 |
Capital Exp. (TTM) (Millions $) |
1 |
Nightstar Therapeutics Plc
Nightstar Therapeutics Plc is a biotechnology company that focuses on the development and commercialization of gene therapies for inherited retinal diseases. The company was founded in 2013 and is headquartered in London, United Kingdom. Nightstar's gene therapies aim to treat conditions such as choroideremia, Stargardt disease, and X-linked retinitis pigmentosa. These diseases cause progressive vision loss and currently have limited treatment options. Nightstar's lead product candidate, NSR-REP1, is a novel gene therapy that aims to slow or halt the progression of choroideremia. The company is dedicated to advancing the field of gene therapy and improving the lives of patients with inherited retinal diseases. In 2019, Nightstar Therapeutics Plc was acquired by Biogen Inc., a global biotechnology company.
|